T Cell Clinical Trials in Houston, Texas
9 recruitingHouston, Texas
Showing 1–9 of 9 trials
Recruiting
Phase 2
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more
Cogent Biosciences, Inc.140 enrolled42 locationsNCT04996875
Recruiting
Phase 1
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive
Baylor College of Medicine90 enrolled2 locationsNCT06176690
Recruiting
Phase 3
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Mycosis FungoidesCutaneous T Cell LymphomaCTCL+1 more
Soligenix80 enrolled17 locationsNCT06470451
Recruiting
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NeoplasmsTenosynovial Giant Cell Tumor
Abbisko Therapeutics Co, Ltd276 enrolled17 locationsNCT04192344
Recruiting
Phase 2
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
Peripheral T Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT06630091
Recruiting
Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.217 enrolled20 locationsNCT05079282
Recruiting
Phase 2
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
T Cells
M.D. Anderson Cancer Center40 enrolled1 locationNCT05411718
Recruiting
Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Peripheral T Cell Lymphoma
Acrotech Biopharma Inc.504 enrolled69 locationsNCT06072131
Recruiting
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
HepatotoxicityTenosynovial Giant Cell Tumor
Daiichi Sankyo30 enrolled8 locationsNCT04635111